Maxime Dely: Anticoagulant Is an Invisible Yet Essential Ally of Therapeutic Apheresis
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Anticoagulant: the invisible yet essential ally of therapeutic apheresis
At first glance, one might think it’s normal saline.
Pearling drops, a steady flow, almost reassuring. And yet… what you’re seeing is far more than a simple solution.
It is an anticoagulant, a fundamental pillar of therapeutic apheresis procedures: ACD-A (Acid Citrate Dextrose – Solution A).
Its mission is clear and essential: to prevent blood from clotting in the extracorporeal circuit during apheresis.
Without it, safe blood processing would simply not be possible.
In practice, anticoagulation ratios can be adjusted depending on the procedure. But not all procedures are equal in terms of duration.
Plasma exchange or red cell exchange typically last 1 to 2 hours.
However, during hematopoietic stem cell collections or lymphocyte collections for CAR-T cell manufacturing, patients may remain connected to the machine for 3 to 6 hours, sometimes processing up to three mass of total blood volumes to achieve the required cell yield.
The specificity of ACD-A?
Citrate chelates calcium, which may lead to hypocalcemia: perioral tingling, metallic taste, chills, tremors… and potentially more severe symptoms if not anticipated.
This is why true expertise in apheresis is essential.
Optimizing a procedure means finding the right balance between collection efficiency, clinical safety, and patient comfort.
It requires close collaboration between nurses, physicians… and industry partners.
Because in apheresis, every single drop matters.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers